<DOC>
	<DOC>NCT00256750</DOC>
	<brief_summary>The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney damage. Effects on kidney function and patient survival as well as drug safety will also be studied.</brief_summary>
	<brief_title>Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>The subject is a recipient of a living donor or deceased donor kidney transplant. Male or Female, 18 or older First time recipient, PRA &gt; 50% or for retransplantation PRA &gt; 30%. If retransplantation, previous graft loss cannot be due to acute rejection. Positive cross match. Subject receiving extended criteria donor (ECD) organ For Longterm extension studySubjects who have completed three years of study treatment (through Week 156)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>